Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen

E. C. Reed, D. Myerson, L. Corey, J. D. Meyers

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Twenty patients who were positive for hepatitis B surface antigen (HBsAg) underwent allogeneic marrow transplant for malignancy or other underlying hematologic disease between 1975 and 1986. After transplant, one patient had serologic evidence of hepatitis B virus (HBV) reactivation whereas three patients had evidence of an immune response to HBV. Among four patients with serologic follow-up of 1 year or more, three remained positive for HBsAg and one became HBsAg negative. Six patients (30%) developed clinical evidence of venocclusive disease and seven patients (35%) developed acute graft-versus-host disease involving the liver, but the incidence of these complications was similar to that expected among patients who are not carriers of HBsAg. Three patients died with hepatorenal failure, but all three had venocclusive disease and the contribution of HBV infection to liver failure was unclear. Available liver specimens obtained at autopsy (six patients) or biopsy (two patients) all showed either HBsAg (one specimen) or hepatitis B core antigen (four specimens) or both (three specimens) by immunoperoxidase staining. Although HBV reactivation leading to hepatic failure has been reported among allogeneic marrow transplant recipients as well as other immunocompromised patients, we did not observe an increase in the incidence of severe liver disease after transplant among these 20 patients positive for HBsAg at the time of transplant, and do not consider positivity for HBsAg to be a contraindication to allogeneic marrow transplantation.

Original languageEnglish (US)
Pages (from-to)195-200
Number of pages6
JournalBlood
Volume77
Issue number1
StatePublished - Jan 1 1991

Fingerprint

Homologous Transplantation
Hepatitis B Surface Antigens
Transplants
Bone Marrow
Viruses
Liver
Hepatitis B virus
Liver Failure
Hepatitis B Core Antigens
Biopsy
Grafts
Hematologic Diseases
Incidence
Immunocompromised Host
Graft vs Host Disease
Virus Diseases
Liver Diseases
Autopsy
Staining and Labeling

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Reed, E. C., Myerson, D., Corey, L., & Meyers, J. D. (1991). Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood, 77(1), 195-200.

Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. / Reed, E. C.; Myerson, D.; Corey, L.; Meyers, J. D.

In: Blood, Vol. 77, No. 1, 01.01.1991, p. 195-200.

Research output: Contribution to journalArticle

Reed, EC, Myerson, D, Corey, L & Meyers, JD 1991, 'Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen', Blood, vol. 77, no. 1, pp. 195-200.
Reed, E. C. ; Myerson, D. ; Corey, L. ; Meyers, J. D. / Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. In: Blood. 1991 ; Vol. 77, No. 1. pp. 195-200.
@article{20d80d7d1dfa43f190dc6487c7d78e13,
title = "Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen",
abstract = "Twenty patients who were positive for hepatitis B surface antigen (HBsAg) underwent allogeneic marrow transplant for malignancy or other underlying hematologic disease between 1975 and 1986. After transplant, one patient had serologic evidence of hepatitis B virus (HBV) reactivation whereas three patients had evidence of an immune response to HBV. Among four patients with serologic follow-up of 1 year or more, three remained positive for HBsAg and one became HBsAg negative. Six patients (30{\%}) developed clinical evidence of venocclusive disease and seven patients (35{\%}) developed acute graft-versus-host disease involving the liver, but the incidence of these complications was similar to that expected among patients who are not carriers of HBsAg. Three patients died with hepatorenal failure, but all three had venocclusive disease and the contribution of HBV infection to liver failure was unclear. Available liver specimens obtained at autopsy (six patients) or biopsy (two patients) all showed either HBsAg (one specimen) or hepatitis B core antigen (four specimens) or both (three specimens) by immunoperoxidase staining. Although HBV reactivation leading to hepatic failure has been reported among allogeneic marrow transplant recipients as well as other immunocompromised patients, we did not observe an increase in the incidence of severe liver disease after transplant among these 20 patients positive for HBsAg at the time of transplant, and do not consider positivity for HBsAg to be a contraindication to allogeneic marrow transplantation.",
author = "Reed, {E. C.} and D. Myerson and L. Corey and Meyers, {J. D.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "77",
pages = "195--200",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen

AU - Reed, E. C.

AU - Myerson, D.

AU - Corey, L.

AU - Meyers, J. D.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Twenty patients who were positive for hepatitis B surface antigen (HBsAg) underwent allogeneic marrow transplant for malignancy or other underlying hematologic disease between 1975 and 1986. After transplant, one patient had serologic evidence of hepatitis B virus (HBV) reactivation whereas three patients had evidence of an immune response to HBV. Among four patients with serologic follow-up of 1 year or more, three remained positive for HBsAg and one became HBsAg negative. Six patients (30%) developed clinical evidence of venocclusive disease and seven patients (35%) developed acute graft-versus-host disease involving the liver, but the incidence of these complications was similar to that expected among patients who are not carriers of HBsAg. Three patients died with hepatorenal failure, but all three had venocclusive disease and the contribution of HBV infection to liver failure was unclear. Available liver specimens obtained at autopsy (six patients) or biopsy (two patients) all showed either HBsAg (one specimen) or hepatitis B core antigen (four specimens) or both (three specimens) by immunoperoxidase staining. Although HBV reactivation leading to hepatic failure has been reported among allogeneic marrow transplant recipients as well as other immunocompromised patients, we did not observe an increase in the incidence of severe liver disease after transplant among these 20 patients positive for HBsAg at the time of transplant, and do not consider positivity for HBsAg to be a contraindication to allogeneic marrow transplantation.

AB - Twenty patients who were positive for hepatitis B surface antigen (HBsAg) underwent allogeneic marrow transplant for malignancy or other underlying hematologic disease between 1975 and 1986. After transplant, one patient had serologic evidence of hepatitis B virus (HBV) reactivation whereas three patients had evidence of an immune response to HBV. Among four patients with serologic follow-up of 1 year or more, three remained positive for HBsAg and one became HBsAg negative. Six patients (30%) developed clinical evidence of venocclusive disease and seven patients (35%) developed acute graft-versus-host disease involving the liver, but the incidence of these complications was similar to that expected among patients who are not carriers of HBsAg. Three patients died with hepatorenal failure, but all three had venocclusive disease and the contribution of HBV infection to liver failure was unclear. Available liver specimens obtained at autopsy (six patients) or biopsy (two patients) all showed either HBsAg (one specimen) or hepatitis B core antigen (four specimens) or both (three specimens) by immunoperoxidase staining. Although HBV reactivation leading to hepatic failure has been reported among allogeneic marrow transplant recipients as well as other immunocompromised patients, we did not observe an increase in the incidence of severe liver disease after transplant among these 20 patients positive for HBsAg at the time of transplant, and do not consider positivity for HBsAg to be a contraindication to allogeneic marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0026032715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026032715&partnerID=8YFLogxK

M3 - Article

C2 - 1984795

AN - SCOPUS:0026032715

VL - 77

SP - 195

EP - 200

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -